Statin use following intracerebral hemorrhage: A decision analysis

Archives of Neurology

Volumn 68, Issue 5, 2011, Pages 573-579

  Westover, M Brandon ^a   Bianchi, Matt T ^a   Eckman, Mark H ^b   Greenberg, Steven M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; DEEP INTRACEREBRAL HEMORRHAGE; DRUG EFFICACY; DRUG INDICATION; DRUG UTILIZATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LOBAR INTRACEREBRAL HEMORRHAGE; MALE; MEDICAL HISTORY; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SURVIVOR; TREATMENT OUTCOME;

AGED; CEREBRAL HEMORRHAGE; CONFOUNDING FACTORS (EPIDEMIOLOGY); DECISION SUPPORT TECHNIQUES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MARKOV CHAINS; MODELS, THEORETICAL; MYOCARDIAL INFARCTION; QUALITY-ADJUSTED LIFE YEARS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STROKE; TREATMENT OUTCOME;

EID: 79953773953     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.356     Document Type: Article

References (44)

1. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(14):1-160.
2. Amarenco P, Bogousslavsky J, Callahan A III, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
3. Jacobs BS, Greenberg SM. Statins, low cholesterol, and hemorrhagic stroke: an uncertain triangle. Neurology. 2008;70(24, pt 2):2355-2356.
4. Goldstein MR, Mascitelli L, Pezzetta F. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2009;72(16):1448-1449.
5. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology. 2001;56(6):773-777. (Pubitemid 32240098)
6. O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med. 2000;342(4):240-245. (Pubitemid 30058955)
7. Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on medical decision analysis: part 1: getting started. Med Decis Making. 1997;17(2):123-125. (Pubitemid 27157026)
8. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677-685. (Pubitemid 29177656)
9. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? a decision analysis. Stroke. 2003;34(7):1710-1716. (Pubitemid 36842632)
10. Plosker GL, Lyseng-Williamson KA. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events. Pharmacoeconomics. 2007;25(12):1031-1053. (Pubitemid 350208907)
11. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150(4):243-254.
12. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164(8):880-884. (Pubitemid 38520629)
13. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology. 2000;55(7):947-951.
14. Woo D, Sauerbeck LR, Kissela BM, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke. 2002;33(5):1190-1195. (Pubitemid 34517033)
15. Rosand J, Greenberg SM. Beyond hypertension: unraveling the causes of intracerebral hemorrhage. Stroke. 2002;33(5):1195-1196. (Pubitemid 34517034)
16. Goldstein LB, Amarenco P, Szarek M, et al; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70(24, pt 2):2364-2370.
17. Smith EE, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Curr Atheroscler Rep. 2003;5(4):260-266. (Pubitemid 38898882)
18. Tzourio C, Arima H, Harrap S, et al. APOE genotype, ethnicity, and the risk of cerebral hemorrhage. Neurology. 2008;70(16):1322-1328. (Pubitemid 351550353)
19. Bae H, Jeong D, Doh J, Lee K, Yun I, Byun B. Recurrence of bleeding in patients with hypertensive intracerebral hemorrhage. Cerebrovasc Dis. 1999;9(2):102-108. (Pubitemid 29084225)
20. Arakawa S, Saku Y, Ibayashi S, Nagao T, Fujishima M. Blood pressure control and recurrence of hypertensive brain hemorrhage. Stroke. 1998;29(9):1806-1809. (Pubitemid 28399968)
21. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke. 1995;26(8):1471-1477.
22. Ariesen MJ, Claus SP, Rinkel GJE, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34(8):2060-2065. (Pubitemid 36944806)
23. Reiss AB, Wirkowski E. Role of HMG-CoA reductase inhibitors in neurological disorders: progress to date. Drugs. 2007;67(15):2111-2120. (Pubitemid 47557089)
24. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21(11):1712-1719. (Pubitemid 34219772)
25. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. Cerebrovasc Dis. 2007;24(2-3):170-182. (Pubitemid 47295581)
26. Meier N, Nedeltchev K, Brekenfeld C, et al. Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke. Stroke. 2009;40(5):1729-1737.
27. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103(18):2248-2253. (Pubitemid 32433713)
28. Notarbartolo A, Davì G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15(2):247-251.
29. Mayer J, Eller T, Brauer P, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 1992;64(4):196-201.
30. Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res. 1999;95(5):229-234. (Pubitemid 29428154)
31. Szapary L, Horvath B, Marton Z, et al. Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia. CNS Drugs. 2004;18(3):165-172. (Pubitemid 38293800)
32. Ural AU, Yilmaz MI, Avcu F, Yalcin A. Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components. Int J Hematol. 2002;76(3):279-283. (Pubitemid 43020318)
33. Essig M, Nguyen G, Prié D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ Res. 1998;83(7):683-690. (Pubitemid 28462781)
34. Essig M, Vrtovsnik F, Nguyen G, Sraer JD, Friedlander G. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol. 1998;9(8):1377-1388. (Pubitemid 28354547)
35. Aarons CB, Cohen PA, Gower A, et al. Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity. Ann Surg. 2007;245(2):176-184. (Pubitemid 46148475)
36. Lai WT, Lee KT, Chu CS, et al. Influence of withdrawal of statin treatment on pro-inflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation. Int J Cardiol. 2005;98(3):459-464.
37. Fogari R, Derosa G, Lazzari P, et al. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens. 2004;17(9):823-827. (Pubitemid 39201099)
38. Orem C, Uydu HA, Yilmaz R, et al. The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients. Jpn Heart J. 2004;45(6):977-987. (Pubitemid 40528868)
39. Undas A, Celinska-Löwenhoff M, Löwenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost. 2006;4(5):1029-1036.
40. Eichel R, Khoury ST, Ben-Hur T, Keidar M, Paniri R, Leker RR. Prior use of statins and outcome in patients with intracerebral haemorrhage. Eur J Neurol. 2010;17(1):78-83.
41. Leker RR, Khoury ST, Rafaeli G, Shwartz R, Eichel R, Tanne D; NASIS Investigators. Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS). Stroke. 2009;40(7):2581-2584.
42. Gomis M, Ois A, Rodríguez-Campello A, et al. Outcome of intracerebral haemorrhage patients pre-treated with statins. Eur J Neurol. 2010;17(3):443-448.
43. Naval NS, Abdelhak TA, Zeballos P, Urrunaga N, Mirski MA, Carhuapoma JR. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit Care. 2008;8(1):6-12. (Pubitemid 351378099)
44. FitzMaurice E, Wendell L, Snider R, et al. Effect of statins on intracerebral hemorrhage outcome and recurrence. Stroke. 2008;39(7):2151-2154.